On May 27, 2024 Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) reported that Verastem Oncology (Nasdaq: VSTM) issued a press release on May 24 that Verastem Oncology has initiated the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for the combination of avutometinib, a RAF/MEK inhibitor, and defactinib, a selective FAK inhibitor, for adult patients with recurrent KRAS mutant low-grade serous ovarian cancer, who received at least one prior systemic therapy (Press release, Chugai, MAY 27, 2024, View Source [SID1234643712]). Avutometinib was created by Chugai, and its clinical development is being conducted by Verastem Oncology.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Please refer to the link below for details of the Verastem Oncology’s press release:
Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
View Source